Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | CTSC | P53634 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1709301 | 1.00 | TSHR (0.47) | TSHRCYP1A2SMN1; SMN2MEN1HTT | |
| SCHEMBL585398 | 0.85 | CYP1A2 (0.59) | TSHRCYP1A2ANPEPERAP1 | |
| Hydrochloric Acid SCHEMBL28284494 | 0.84 | CYP1A2 (0.57) | TSHRCYP1A2ANPEPERAP1 | |
| SCHEMBL7483571 | 0.82 | ERAP1 (0.51) | TSHRCYP1A2SMN1; SMN2MEN1HTT | |
| SCHEMBL1709339 | 0.81 | CYP1A2 (0.64) | CYP1A2ANPEP | |
| SCHEMBL1709283 | 0.81 | CYP1A2 (0.64) | CYP1A2ANPEP | |
| SCHEMBL8903502 | 0.80 | TSHR (0.49) | TSHRSMN1; SMN2MEN1HTTKMT2A | |
| SCHEMBL9613415 | 0.80 | CNR2 (0.49) | TSHRSMN1; SMN2MEN1HTTKMT2A | |
| SCHEMBL18085413 | 0.79 | SMN1; SMN2 (0.55) | TSHRSMN1; SMN2MEN1KMT2A | |
| SCHEMBL19656196 | 0.79 | TSHR (0.45) | TSHRCYP1A2SMN1; SMN2MEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CORPORATION (JP) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | TSHR 3526/4885CYP1A2 3371/4885SMN1; SMN2 1774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.